Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C, Ibrahim M, Maillart E, Abdi B, Papeix C, Stankoff B, Dubessy AL, Bensa-Koscher C, Créange A, Chamekh Z, Lubetzki C, Marcelin AG, Corvol JC, Pourcher V; COVISEP and Bio-coco-neuroscience study group. Louapre C, et al. Among authors: maillart e. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):24-31. doi: 10.1136/jnnp-2021-326904. Epub 2021 Aug 2. J Neurol Neurosurg Psychiatry. 2022. PMID: 34341142 Clinical Trial.
Efficacy of rituximab in refractory neuromyelitis optica.
Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP. Collongues N, et al. Among authors: maillart e. Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362900
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP. Ciron J, et al. Among authors: maillart e. Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Rev Neurol (Paris). 2018. PMID: 29606320 Review. English.
The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study.
Chazal T, Costopoulos M, Maillart E, Fleury C, Psimaras D, Legendre P, Pineton de Chambrun M, Haroche J, Lubetzki C, Amoura Z, Legarff-Tavernier M, Cohen Aubart F. Chazal T, et al. Among authors: maillart e. Eur J Neurol. 2019 Oct;26(10):1274-1280. doi: 10.1111/ene.13975. Epub 2019 Jun 24. Eur J Neurol. 2019. PMID: 31021023 Free article. Clinical Trial.
Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients.
Shor N, Aboab J, Maillart E, Lecler A, Bensa C, Le Guern G, Grunbaum S, Marignier R, Papeix C, Heron E, Gout O, Savatovsky J, Galanaud D, Vignal C, Touitou V, Deschamps R. Shor N, et al. Among authors: maillart e. Eur J Neurol. 2020 Feb;27(2):384-391. doi: 10.1111/ene.14089. Epub 2019 Oct 20. Eur J Neurol. 2020. PMID: 31532865
MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests.
Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A. Maillart E, et al. Eur J Neurol. 2020 Mar;27(3):429-436. doi: 10.1111/ene.14091. Epub 2019 Oct 19. Eur J Neurol. 2020. PMID: 31538396 Clinical Trial.
210 results